The effects of metformin on ovarian cancer: A systematic review

International Journal of Gynecological Cancer

Volumn 23, Issue 9, 2013, Pages 1544-1551

  Dilokthornsakul, Piyemeth ^a,h   Chaiyakunapruk, Nathorn ^a,b,c,d   Termrungruanglert, Wichai ^e   Pratoomsoot, Chayanin ^f   Saokaew, Surasak ^a,g   Sruamsiri, Rosarin ^a  

^a Faculty of Pharmaceutical Sciences   (Thailand)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c UNIVERSITY OF WISCONSIN MADISON   (United States)

^d MONASH UNIVERSITY MALAYSIA   (Malaysia)

^e CHULALONGKORN UNIVERSITY   (Thailand)

^f Naresuan University   (Malaysia)

^g UNIVERSITY OF PHAYAO   (Thailand)

^h UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Diabetes mellitus; Meta analysis; Metformin; Ovarian cancer; Systematic review

Indexed keywords

INSULIN; METFORMIN; SULFONYLUREA;

ANTINEOPLASTIC ACTIVITY; CANCER PATIENT; CANCER PREVENTION; CANCER RISK; CANCER SURVIVAL; CASE CONTROL STUDY; DIABETES MELLITUS; DIABETIC PATIENT; DISEASE SPECIFIC SURVIVAL; DRUG EFFECT; FOLLOW UP; HUMAN; MEDICAL RECORD REVIEW; META ANALYSIS; OBSERVATIONAL STUDY; OVARY CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

CASE-CONTROL STUDIES; COHORT STUDIES; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; OVARIAN NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84888334337     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0b013e3182a80a21     Document Type: Review

References (36)

1. American Cancer Society. Ovarian Cancer. 2012. Available at: http://www.cancer.org/cancer/ovariancancer/detailedguide/ovarian-cancer-key- statistics. Accessed January 17, 2013.
2. National Cancer Institute. SEER Stat Fact Sheets: Ovary. 2012. Available at: http://seer.cancer.gov/statfacts/html/ovary.html. Accessed January 17, 2013.
3. American Cancer Society. Global Cancer Facts & Figures. 2nd ed. Atlanta, GA: American Cancer Society; 2011.
4. Roett MA, Evans P. Ovarian cancer: an overview. Am Fam Physician. 2009; 80: 609-616.
5. Bakhru A, Buckanovich RJ, Griggs JJ. The impact of diabetes on survival in women with ovarian cancer. Gynecol Oncol. 2011; 121: 106-111.
6. Weiderpass E, Ye W, Vainio H, et al. Diabetes mellitus and ovarian cancer (Sweden). Cancer Causes Control. 2002; 13: 759-764.
7. Ben Sahra I, Le Marchand-Brustel Y, Tanti JF, et al. Metformin in cancer therapy: a new perspective for an old antidiabetic drug? Mol Cancer Ther. 2010; 9: 1092-1099.
8. Baur DM, Klotsche J, Hamnvik OP, et al. Type 2 diabetes mellitus and medications for type 2 diabetes mellitus are associated with risk for and mortality from cancer in a German primary care cohort. Metabolism. 2010; 60: 1363-1371.
9. Bowker SL, Yasui Y, Veugelers P, et al. Glucose-lowering agents and cancer mortality rates in type 2 diabetes: assessing effects of time-varying exposure. Diabetologia. 2010; 53: 1631-1637.
10. Gotlieb WH, Saumet J, Beauchamp MC, et al. In vitro metformin anti-neoplastic activity in epithelial ovarian cancer. Gynecol Oncol. 2008; 110: 246-250.
11. Rattan R, Giri S, Hartmann LC, et al. Metformin attenuates ovarian cancer cell growth in an AMP-kinase dispensable manner. J Cell Mol Med. 2009; 15: 166-178.
12. Berstein LM. Metformin in obesity, cancer and aging: addressing controversies. Aging (Albany NY). 2012; 4: 320-329.
13. Wells G, Shea B, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2011. Available at: http://www.ohri.ca/programs/clinical-epidemiology/oxford.asp. Accessed December 20, 2012.
14. Higgins JPT, Altman DG, Sterne JAC. Assessing risk of bias in included studies. In: Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2: The Cochrane Collaboration. 2009. Updated September 2009. Available at www.cochrane-handbook.org.
15. Der Simonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986; 7: 177-188.
16. Higgins J, Thompson S. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002; 21: 1539-1558.
17. Begg C, Berlin J. Publication bias and dissemination of clinical research. J Natl Cancer Inst. 1989; 81: 107-115.
18. Bodmer M, Becker C, Meier C, et al. Use of metformin and the risk of ovarian cancer: a case-control analysis. Gynecol Oncol. 2011; 123: 200-204.
19. Home PD, Kahn SE, Jones NP, et al. Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia. 2010; 53: 1838-1845.
20. Kumar S, Meuter A, Thapa P, et al. Metformin intake is associated with better survival in ovarian cancer: a case-control study. Cancer. 2013; 119: 555-562.
21. Romero IL, McCormick A, McEwen KA, et al. Relationship of type II diabetes and metformin use to ovarian cancer progression, survival, and chemosensitivity. Obstet Gynecol. 2012; 119: 61-67.
22. Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006; 355: 2427-2443.
23. Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet. 2009; 373: 2125-2135.
24. Bodmer M, Meier C, Krahenbuhl S, et al. Long-term metformin use is associated with decreased risk of breast cancer. Diabetes Care. 2010; 33: 1304-1308.
25. DeCensi A, Puntoni M, Goodwin M, et al. Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prev Res. 2010; 3:OF1YOF11.
26. Hassan MM, Curley SA, Li D, et al. Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma. Cancer. 2010; 116: 1938-1946.
27. Landman GW, Kleefstra N, van Hateren KJ, et al. Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16. Diabetes Care. 2010; 33: 322-326.
28. Noto H, Goto A, Tsujimoto T, et al. Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis. PLoS ONE. 2012; 7:e33411.
29. Lee MS, Hsu CC,Wahlqvist ML, et al. Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800,000 individuals. BMC Cancer. 2011; 11:20.
30. Kourelis TV, Siegel RD. Metformin and cancer: new applications for an old drug. Med Oncol. 2012; 29: 1314-1327.
31. Shackelford DB, Shaw RJ. The LKB1-AMPK pathway: metabolism and growth control in tumour suppression. Nat Rev Cancer. 2009; 9: 563-575.
32. Yasmeen A, Beauchamp MC, Piura E, et al. Induction of apoptosis by metformin in epithelial ovarian cancer: involvement of the Bcl-2 family proteins. . Gynecol Oncol. 2011; 121: 492-498.
33. Rattan R, Giri S, Hartmann LC, et al. Metformin attenuates ovarian cancer cell growth in an AMP-kinase dispensable manner. J Cell Mol Med. 2011; 15: 166-178.
34. Shank JJ, Yang K, Ghannam J, et al. Metformin targets ovarian cancer stem cells in vitro and in vivo. Gynecol Oncol. 2012; 127: 390-397.
35. Morgan RJ, Alvarez RD, Armstrong DK, et al. NCCN clinical practice guideline in oncology (NCCN guideline): ovarian cancer including fallopian tube cancer and primary peritoneal cancer. 2013. Available at: http://www.nccn.org/ professionals/physician-gls/pdf/ovarian.pdf. Accessed July 2, 2013.
36. Erices R, Bravo ML, Gonzalez P, et al. Metformin, at concentrations corresponding to the treatment of diabetes, potentiates the cytotoxic effects of carboplatin in cultures of ovarian cancer cells. Reprod Sci. 2013; published online May 7, 2013.